Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothe...
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluo...
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas
- Conditions
- First Posted Date
- 2003-09-25
- Last Posted Date
- 2013-02-18
- Lead Sponsor
- Duke University
- Registration Number
- NCT00003463
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-09-25
- Last Posted Date
- 2020-04-29
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1691
- Registration Number
- NCT00003594
- Locations
- 🇺🇸
Hematology Oncology Associates of Illinois - Lake Shore Dr, Chicago, Illinois, United States
🇺🇸Grady Memorial Hospital, Atlanta, Georgia, United States
🇺🇸Emory University Hospital - Atlanta, Atlanta, Georgia, United States
Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-09-24
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00003245
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer
- Conditions
- Rectal Signet Ring Cell AdenocarcinomaStage IIA Rectal Cancer AJCC v7Stage IIIA Rectal Cancer AJCC v7Stage IIIB Rectal Cancer AJCC v7Rectal Mucinous AdenocarcinomaRecurrent Rectal CarcinomaStage IIC Rectal Cancer AJCC v7Stage IIB Rectal Cancer AJCC v7Stage IVA Rectal Cancer AJCC v7Stage IIIC Rectal Cancer AJCC v7
- Interventions
- First Posted Date
- 2003-09-11
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 225
- Registration Number
- NCT00068692
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Carboplatin Plus Irinotecan in Treating Patients With Glioblastoma Multiforme
- Conditions
- First Posted Date
- 2003-09-04
- Last Posted Date
- 2011-03-28
- Lead Sponsor
- NYU Langone Health
- Registration Number
- NCT00010036
- Locations
- 🇺🇸
NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States
Combination Chemotherapy in Treating Patients With Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-09-03
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 400
- Registration Number
- NCT00006103
S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2012-11-02
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 45
- Registration Number
- NCT00066612
Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer
- Conditions
- Locations
- 🇬🇧
Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom
🇧🇪U.Z. Gasthuisberg, Leuven, Belgium
🇭🇺National Institute of Oncology, Budapest, Hungary
Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary
- Conditions
- Interventions
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 31
- Registration Number
- NCT00066781
- Locations
- 🇺🇸
Cancer Resource Center - Lincoln, Lincoln, Nebraska, United States
🇺🇸Mercy Cancer Center at Mercy Medical Center - North Iowa, Mason City, Iowa, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2021-03-02
- Lead Sponsor
- UNICANCER
- Registration Number
- NCT00066274
- Locations
- 🇫🇷
Centre Regional Francois Baclesse, Caen, France
🇫🇷Centre Eugene Marquis, Rennes, France
🇫🇷Centre Antoine Lacassagne, Nice, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.